Dexcom plans to support the first commercial launch of an automated insulin delivery system using TypeZero’s inControl algorithm next year.
In March, Dexcom’s latest continuous glucose monitor became the first CGM to be approved by the FDA as fully interoperable with other medical devices.
“As the first iCGM designated by the FDA, Dexcom again has the opportunity to lead the market for integrated systems for diabetes management. TypeZero is a great fit for Dexcom as we look to deliver a growing set of tools to both our insulin delivery partners and our customers,” Steve Pacelli, Dexcom’s EVP of strategy & corporate development, said in prepared remarks. “Combined with best-in-class CGM technology, we believe TypeZero’s technology and strong team will accelerate our efforts to further differentiate Dexcom’s portfolio.”
“The TypeZero team is excited for our next chapter as part of Dexcom,” Chad Rogers, TypeZero’s CEO, added. “For the last several years, our company has been committed to creating diabetes management products that simplify the life of a person with diabetes. As part of Dexcom, we will continue to embrace the mission to empower people with diabetes through innovation.”